TL;DR
This study investigates the relationship between specific adipokines (adiponectin, adipsin, and visfatin) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), finding that higher adipsin and lower adiponectin levels are associated with MAFLD. Importantly, the strength of these associations varies depending on which diagnostic criteria (BMI, metabolic dysregulation, or type 2 diabetes) are used to define MAFLD.
What Problem Does This Paper Address?
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) is a relatively new definition proposed in 2020, aiming to better capture fatty liver disease driven by systemic metabolic dysfunction. While non-alcoholic fatty liver disease (NAFLD) has been studied extensively, the specific biomarkers associated with MAFLD, particularly adipokines (hormones secreted by fat tissue that regulate metabolism), are not well understood. Adipokines like adiponectin, adipsin, and visfatin are known to play roles in metabolic homeostasis, and their dysregulation is linked to various metabolic disorders. However, their precise association with MAFLD, especially considering the different diagnostic criteria for MAFLD, remains unclear. This paper aims to fill this knowledge gap by examining these associations.
Methods
The researchers conducted a cross-sectional study involving 221 participants who underwent medical examinations. Data collected included detailed questionnaires on lifestyle and demographics, physical examinations (measuring height, weight, waist circumference, hip circumference, and blood pressure), abdominal ultrasounds for liver steatosis assessment, and blood biochemical tests. Adipokine levels (adiponectin, adipsin, and visfatin) were measured using enzyme immunoassay techniques.
Statistical analysis involved:
- Univariate comparisons: T-tests and Mann-Whitney U tests were used to compare characteristics between the MAFLD and non-MAFLD groups.
- Logistic regression models: These were employed to assess the associations between adipokine levels and MAFLD. The analysis considered different diagnostic criteria for MAFLD:
- BMI: Overweight/obesity defined as BMI ≥ 23 kg/m² in Asians.
- Metabolic Dysregulation (MD): Defined by having at least two metabolic risk abnormalities (e.g., elevated waist circumference, high blood pressure, dyslipidemia, prediabetes).
- Type 2 Diabetes Mellitus (T2DM): Defined by fasting glucose levels ≥ 7.0 mmol/L or a history of T2DM.
- Tertile analysis: Adipokine levels were divided into tertiles, with the lowest tertile serving as the reference group to evaluate dose-response relationships.
- Model adjustments: Logistic regression models were used both in crude form (Model 1) and adjusted for potential confounders such as age, gender, smoking, drinking, physical activity, AST, and ALT (Model 2).
Datasets
The study utilized data from 221 participants recruited from the Physical Examination Center of the Third Affiliated Hospital of Sun Yat-sen University between April 2016 and September 2016. This constitutes a single, prospectively collected dataset for this study. No external or publicly available datasets were used for training or evaluation.
Key Insights and Ideas
- Adipokines as potential MAFLD markers: The study highlights adiponectin and adipsin as potential biomarkers for MAFLD, with distinct inverse and positive associations, respectively.
- Diagnostic criteria matter: The most striking insight is that the strength and significance of the associations between adipokines and MAFLD are influenced by the specific diagnostic criteria used. This suggests that MAFLD is not a monolithic entity and its underlying metabolic drivers might differ based on how it's diagnosed.
- Visfatin's elusive role: Visfatin, another adipokine, showed no significant association with MAFLD across any of the diagnostic criteria, suggesting its role in this specific condition might be less pronounced or more complex than adiponectin and adipsin.
- MAFLD vs. NAFLD nuances: The shift from NAFLD to MAFLD emphasizes metabolic dysfunction. This study directly addresses this by linking adipokines, known metabolic regulators, to MAFLD.
Key Results
- Adiponectin: Lower levels of adiponectin were consistently found in the MAFLD group compared to the non-MAFLD group. Adiponectin showed an inverse association with MAFLD (higher tertiles associated with lower MAFLD risk). This inverse association was strongest when T2DM was used as the sole diagnostic criterion for MAFLD.
- Adipsin: Higher levels of adipsin were observed in the MAFLD group. Adipsin demonstrated a positive association with MAFLD (higher tertiles associated with higher MAFLD risk). This positive association was strongest when BMI was used as the sole diagnostic criterion for MAFLD.
- Visfatin: No statistically significant association was found between visfatin levels and MAFLD, regardless of the diagnostic criterion used (BMI, MD, or T2DM).
- Metabolic Dysregulation (MD): Participants with metabolic dysregulation (MD) had lower adiponectin and higher adipsin levels compared to those without MD.
Limitations and Future Work
The authors acknowledge several limitations:
- Descriptive nature: The study is descriptive and can only establish epidemiological associations, not causal inferences.
- Missing data: The study could not investigate the effects of HOMA-IR and hs-CRP due to a lack of data.
- Gender bias: The participant pool was predominantly male, limiting the generalizability of findings to women.
Future work should focus on:
- Mechanistic studies: Investigating the causal relationships and molecular mechanisms underlying these adipokine-MAFLD associations.
- Large-scale prospective studies: To validate these findings and explore the potential of adipokines as biomarkers for MAFLD under different diagnostic conditions.
- Inclusion of women: Future studies should aim for a more balanced gender representation to ensure broader applicability of the results.
- Exploring other diagnostic criteria: Further research could explore the impact of other combinations or refined definitions of metabolic dysregulation on adipokine associations.
Summary updated